Lifesci Capital Issues Negative Outlook for TNYA Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Investment analysts at Lifesci Capital reduced their Q2 2025 earnings estimates for shares of Tenaya Therapeutics in a note issued to investors on Thursday, July 31st. Lifesci Capital analyst C. Jubinville now expects that the company will post earnings per share of ($0.24) for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics’ Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.96) EPS.

TNYA has been the topic of several other reports. Chardan Capital restated a “buy” rating and set a $9.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, May 9th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, April 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $6.25.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $0.67 on Monday. The company has a market capitalization of $109.09 million, a price-to-earnings ratio of -0.58 and a beta of 3.01. Tenaya Therapeutics has a one year low of $0.36 and a one year high of $4.01. The company’s fifty day moving average price is $0.64 and its 200-day moving average price is $0.69.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06).

Institutional Trading of Tenaya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC bought a new stake in Tenaya Therapeutics in the 4th quarter valued at $45,000. Northern Trust Corp grew its stake in shares of Tenaya Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 472,479 shares of the company’s stock worth $676,000 after buying an additional 27,632 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Tenaya Therapeutics in the 1st quarter worth $33,000. Deutsche Bank AG grew its stake in shares of Tenaya Therapeutics by 304.1% in the 4th quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock worth $185,000 after buying an additional 97,318 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Tenaya Therapeutics by 25.2% in the 4th quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company’s stock worth $494,000 after buying an additional 69,377 shares in the last quarter. 90.54% of the stock is currently owned by institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.